Approaches to Ras signaling modulation and treatment of Ras-dependent disorders: a patent review (2007--present). (Q38046230)

27 August 2017

title

Approaches to Ras signaling modulation and treatment of Ras-dependent disorders: a patent review (2007--present). (English)

1 reference

27 August 2017

Marco Vanoni

3

0 references

author name string

Elena Sacco

series ordinal

1

1 reference

27 August 2017

Michela Spinelli

series ordinal

2

1 reference

27 August 2017

language of work or name

English

0 references

publication date

26 September 2012

1 reference

Expert Opinion on Therapeutic Patents

27 August 2017

published in

1 reference

27 August 2017

volume

22

1 reference

27 August 2017

issue

11

1 reference

27 August 2017

page(s)

1263-1287

1 reference

RAS oncogenes: weaving a tumorigenic web

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Ras redux: rethinking how and where Ras acts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Signaling interplay in Ras superfamily function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

The guanine nucleotide-binding switch in three dimensions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

GEFs and GAPs: critical elements in the control of small G proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Ras proteins: paradigms for compartmentalised and isoform-specific signalling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Ras trafficking, localization and compartmentalized signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Palmitoylation and localisation of RAS isoforms are modulated by the hypervariable linker domain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Regulating the regulator: post-translational modification of RAS

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Feedback regulation of Ras signaling by Rabex-5-mediated ubiquitination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

H-Ras is degraded by Wnt/beta-catenin signaling via beta-TrCP-mediated polyubiquitylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Ubiquitination of K-Ras enhances activation and facilitates binding to select downstream effectors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Distinct rates of palmitate turnover on membrane-bound cellular and oncogenic H-ras

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Depalmitoylated Ras traffics to and from the Golgi complex via a nonvesicular pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

An acylation cycle regulates localization and activity of palmitoylated Ras isoforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Palmitoylation of intracellular signaling proteins: regulation and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Signal transduction by receptors with tyrosine kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Guanine-nucleotide-releasing factor hSos1 binds to Grb2 and links receptor tyrosine kinases to Ras signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Regulation of Sos activity by intramolecular interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Regulation of hSos1 activity is a system-level property generated by its multi-domain structure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

A growing family of guanine nucleotide exchange factors is responsible for activation of ras-family GTPases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

p120-Ras GTPase activating protein (RasGAP): a multi-interacting protein in downstream signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Targeting RAS signalling pathways in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

The phosphoinositide 3-kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

The life of a cell: apoptosis regulation by the PI3K/PKB pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Activation of the nuclear factor-kappaB by Rho, CDC42, and Rac-1 proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Targeting group II PAKs in cancer and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

RalGDS family members couple Ras to Ral signalling and that's not all.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Ral-GTPases: approaching their 15 minutes of fame

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Activation of RalA is critical for Ras-induced tumorigenesis of human cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Phospholipase C epsilon: linking second messengers and small GTPases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

A comprehensive survey of Ras mutations in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Selective cytotoxicity of a bicyclic Ras inhibitor in cancer cells expressing K-Ras(G13D).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

K-ras codon-specific mutations produce distinctive metabolic phenotypes in NIH3T3 mice [corrected] fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

RAS in cellular transformation and senescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Ras oncogenes: split personalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Essential role for oncogenic Ras in tumour maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Oncogenic K-Ras signals through epidermal growth factor receptor and wild-type H-Ras to promote radiation survival in pancreatic and colorectal carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Germline KRAS mutations cause Noonan syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Neurofibromatosis 1: closing the GAP between mice and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Farnesyltransferase inhibitors: where are we now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Targeting protein prenylation for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Small molecule inhibition of protein depalmitoylation as a new approach towards downregulation of oncogenic Ras signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL on mitochondria and induces apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Stabilizing a weak binding state for effectors in the human ras protein by cyclen complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

The anti-inflammatory TIPE2 is an inhibitor of the oncogenic Ras.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Inhibition of Ras for cancer treatment: the search continues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Recent developments in anti-cancer agents targeting the Ras/Raf/ MEK/ERK pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

MEK inhibitors: a patent review 2008 - 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Characterization of ERK docking domain inhibitors that induce apoptosis by targeting Rsk-1 and caspase-9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

p21-Activated kinase inhibitors: a patent review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Development of small-molecule inhibitors of the group I p21-activated kinases, emerging therapeutic targets in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

The RalGEF-Ral Effector Signaling Network: The Road Less Traveled for Anti-Ras Drug Discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Reovirus as a novel oncolytic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

New developments in the virus therapy of cancer: a historical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

A lethal combination for cancer cells: synthetic lethality screenings for drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Use of isogenic human cancer cells for high-throughput screening and drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Interruption of RNA processing machinery by a small compound, 1-[(4-chlorophenyl)methyl]-1H-indole-3-carboxaldehyde (oncrasin-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Effects of a new centrally acting muscle relaxant, NK433 (lanperisone hydrochloride) on spinal reflexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

A-type lamins and Hutchinson-Gilford progeria syndrome: pathogenesis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

First experimental identification of Ras-inhibitor binding interface using a water-soluble Ras ligand.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Design, synthesis and biological evaluation of sugar-derived Ras inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Ras oncoprotein inhibitors: the discovery of potent, ras nucleotide exchange inhibitors and the structural determination of a drug-protein complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Discovery of Small Molecules that Bind to K-Ras and Inhibit Sos-Mediated Activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Characterization and properties of dominant-negative mutants of the ras-specific guanine nucleotide exchange factor CDC25(Mm).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

The isolated catalytic hairpin of the Ras-specific guanine nucleotide exchange factor Cdc25Mm retains nucleotide dissociation activity but has impaired nucleotide exchange activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

A dominant negative RAS-specific guanine nucleotide exchange factor reverses neoplastic phenotype in K-ras transformed mouse fibroblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Novel RasGRF1-derived Tat-fused peptides inhibiting Ras-dependent proliferation and migration in mouse and human cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

An orthosteric inhibitor of the Ras-Sos interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Guanosine triphosphatase stimulation of oncogenic Ras mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Substrate assisted catalysis -- application to G proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Antiapoptotic signaling generated by caspase-induced cleavage of RasGAP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

A p53-inducible microRNA-34a downregulates Ras signaling by targeting IMPDH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

STK33 kinase activity is nonessential in KRAS-dependent cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Systems biology and the molecular circuits of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

A robustness-based approach to systems-oriented drug design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Structure of protein interaction networks and their implications on drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Metabolic control analysis indicates a change of strategy in the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

21 January 2018

Biological robustness

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Metabolic reprogramming: a cancer hallmark even warburg did not anticipate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

Breathless cancer cells get fat on glutamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.728586

10.1517/13543776.2012.728586

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference